Tyrosine kinase inhibitor, lenvatinib, alone or in combination with other agents has been found as a potent anti-VEGFR agent in the primitive bone tumor, including giant cell tumors of bone (GCTB) [44]. This evidence concerns the gene KDR and bone neoplasm.